Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
Mayhem hits the metals market—where are prices heading?
08:13pm, Monday, 10'th Oct 2022
CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Dan Nathan, Karen Finerman, and Courtney Garcia discuss traditional inflation hedges, new opportunities for safe haven investments, and gold p
Guggenheim's Seamus Fernandez offers his bullish case for Merck
05:03pm, Monday, 10'th Oct 2022
Seamus Fernandez, Guggenheim Securities, joins 'Closing Bell: Overtime' to discuss Guggenheim's upgrade for Merck.
Failure Of This Merck Study Is A 'Material Risk' But Analysts Are 'Extremely Bullish'
02:39pm, Monday, 10'th Oct 2022 Benzinga
Merck & Co. Inc. (NYSE: MRK) seems well positioned to surpass 2023 consensus estimates, driven by margin potential, according to Guggenheim.
The Analyst: Seamus Fernandez upgraded the rating for Merck
Merck (MRK) Stock Jumps 4% on Positive Trial Data
02:25pm, Monday, 10'th Oct 2022
Despite a rough day outing on Monday for the major equity indices, shares of pharmaceutical giant Merck (NYSE: MRK ) swung higher. Early this morning, the company announced positive top-line results f
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2022
02:08pm, Monday, 10'th Oct 2022 Benzinga
Upgrades
OTR Global upgraded the previous rating for Restaurant Brands International Inc (NYSE:QSR) from Mixed to Positive. For the second quarter, Restaurant Brands Intl had an EPS of $0.82, compared
Stock Market News for Oct 10, 2022
01:16pm, Monday, 10'th Oct 2022 Zacks Investment Research
U.S. stock markets closed sharply lower on Friday following stronger-than-expected job data for September.
Large number of U.S. COVID deaths could be prevented if patients would take Pfizer's Paxlovid, White House coordinator warns
12:07pm, Monday, 10'th Oct 2022 MarketWatch
A large number of U.S. COVID deaths could be prevented if patients would take Paxlovid, the antiviral developed by Pfizer that helps reduce the risk of hospitalization and death, according to White Ho
MDA Breakout Stocks Week 41- October 2022: Short-Term Picks To Give You An Edge
10:04am, Monday, 10'th Oct 2022
Two new Breakout Stocks for Week 41 with better than 10% short-term upside potential and one Dow 30 pick. Average cumulative returns now up to +106.5% YTD. This week one pick beat 10% in less than a w
Merck Scores A 'Must-Win' For Its $11.5 Billion Acceleron Buyout
09:49am, Monday, 10'th Oct 2022
Merck stock jumped Monday after a drug its acquired for billions scored a "must-win" in patients with a rare blood pressure condition. The post Merck Scores A 'Must-Win' For Its $11.5 Billion Accelero
5 Relatively Safe And Cheap Dividend Stocks To Invest In - October 2022
01:00pm, Saturday, 08'th Oct 2022 Seeking Alpha
This article is part of our monthly series where we scan the entire universe of ~7,500 stocks that are listed on U.S. exchanges. See our 5 picks for Oct. 2022.
3 Great Dividend Stocks to Buy in October
10:05am, Saturday, 08'th Oct 2022 The Motley Fool
Their dividends should be much bigger in the future.
10 Dividend Growth Stocks For October 2022
09:00am, Saturday, 08'th Oct 2022
After two months off, I'm back with another edition of my monthly series, 10 Dividend Growth Stocks. I rank a selection of dividend growth stocks in Dividend Radar and present the ten top-ranked stock
3 Great Dividend Stocks to Buy in October
06:05am, Saturday, 08'th Oct 2022
Their dividends should be much bigger in the future.
Why Guardant Health Topped the Market on Thursday
10:02pm, Thursday, 06'th Oct 2022 The Motley Fool
Add another name to the list of the cancer-diagnostic company's bulls.
Verve's Stock Price Could Continue To Rise Through Clinical Progress - Despite Worries About "DeeperPocketed" Competition
07:49pm, Thursday, 06'th Oct 2022 Benzinga
Credit Suisse has initiated coverage on Verve Therapeutics Inc (NASDAQ: VERV) with a Neutral rating and a $48 target price.
Its lead assets are VERVE-101 for heterozygous familial hypercholester
